Hubei Huisheng Biotechnology Co., Ltd. announced that it will receive CNY 700 million in an equity round of funding through capital increase from retuning investor Hvsen Biotechnology Co., Ltd. to retain 100% stake in the company on October 25, 2022. After the completion of this capital increase, the registered capital of will be increased from CNY 300 million to CNY 1,000 million. The transaction has been approved at the 28th meeting of the second board of directors and the 23rd meeting of the second board of supervisors and does not need to be submitted to the company's general meeting of shareholders for consideration.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.98 CNY | -1.24% | -16.98% | -17.15% |
05-23 | Hvsen Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 | CI |
04-25 | Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.15% | 270M | |
-14.09% | 77.37B | |
+18.66% | 8.74B | |
+23.75% | 3.67B | |
-0.42% | 3.25B | |
+18.07% | 1.73B | |
-16.99% | 1.38B | |
-26.05% | 1.24B | |
-17.86% | 1.07B | |
-6.77% | 976M |
- Stock Market
- Equities
- 300871 Stock
- News Hvsen Biotechnology Co., Ltd.
- Hubei Huisheng Biotechnology Co., Ltd. announced that it expects to receive CNY 700 million in funding from Hvsen Biotechnology Co., Ltd.